Category: CHRYSALIS Study

Janssen Presents Results of Rybrevant (amivantamab-vmjw) in P-I CHRYSALIS Study for Advanced NSCLC with METex14 Mutations at WCLC

Shots: The P-I CHRYSALIS study evaluates the safety, PK, and preliminary efficacy of Rybrevant (1050/1400 mg) as a monothx. and in combinations with lazertinib in 19 patients with NSCLC with METex14 mutations The initial data showed anti-tumor activity and a consistent safety profile with reported experience at the approved P-II dose. Disease response was evaluated […]

Janssen Reports Updated Data of Amivantamab + Lazertinib in P-I CHRYSALIS Study for EGFR-Mutated NSCLC

Shots: The CHRYSALIS study involves assessing amivantamab as a monothx. and in combination with Lazertinib in 460 patients with advanced NSCLC with various EGFR mutations The updated data showed mDOR of 9.6mos. in CT-naïve patients with NSCLC & EGFR exon 19 deletion or L858R mutations whose disease had progressed after treatment with osimertinib. These results […]